ArticleFrontiers in endocrinology2025
Combining biomarkers to predict the disease activity of graves' ophthalmopathy: a combinatory model of the NLR, TRAb and FT4.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association between serum immunoglobulin G4 levels and Graves' ophthalmopathy: a meta-analysis.Frontiers in endocrinology · 2026Pooled it
- Peripheral blood inflammatory indices across thyroid functional states in Graves' disease: associations with liver biochemical abnormalities and hyperthyroid relapse.Frontiers in endocrinology · 2026Article
- A combined model of BCVA, TRAb, and NLR predicts response to intravenous methylprednisolone in dysthyroid optic neuropathy.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The aim of this study was to identify potential biomarkers associated with active Graves' ophthalmopathy (GO) and develop a model for predicting the occurrence and progression of active GO. Methods: A retrospective study was conducted on 220 GO patients (n=120 in the active phase, n=100 in the stable phase) and 70 healthy controls. Laboratory and other clinical indicators were compared in GO patients at different stages and healthy controls. A multivariate regression analysis model was used to analyze the clinical risk factors affecting the occurrence and progression of active GO, and a predictive model based on risk factors was established. Results: Higher WBC, NEU, NLR, TRAb and FT4 levels (all p<0.005) were detected in patients with active GO than those in inactive GO. The CAS score of the GO patients was positively correlated with the WBC (r = 0.155, p = 0.003), NEU (r = 0.165, p = 0.002), NLR (r = 0.134, p = 0.010), FT3 (r = 0.117, p = 0.031), FT4 (r = 0.139, p = 0.011), and TRAb (r = 0.160, p = 0.004) counts and negatively correlated with the TSH level (r = - 0.114, p = 0.043). Multivariate regression analysis revealed that the NLR, TRAb, and FT4 were significant risk factors for GO progression (all p < 0.05). The cut-off levels for predicting active GO were 8.71 IU/L for TRAb (AUC=0.643, sensitivity 0.58, specificity 0.74), 19.82 ng/dL for FT4 (AUC=0.606, sensitivity 0.41, specificity 0.75), and 2.405 for the NLR (AUC=0.597, sensitivity 0.50, specificity 0.75). A predictive model including these risk factors was built (the cutoff value was 0.6, the AUC was 0.716, the sensitivity was 0.533, and the specificity was 0.808). Conclusion: The laboratory biomarkers for the occurrence and progression of active GO include the NLR, FT4, and TRAb. We have developed a predictive combined model that may assist in timely assessment of GO activity and progression, and provide clues for future development of facile tools to predict GO activity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.